What’s Next? Five Things To Look Out For In March
Bristol Myers Squibb Braces For US Impact To Revlimid And Abraxane
This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.
You may also be interested in...
Generic versions of Revlimid have been launched in countries across Europe, with Sandoz and Stada among those to have confirmed the introduction of lenalidomide in numerous European markets. Meanwhile, US competition to Revlimid is expected next month.
Fresh from announcing a major deal that will see it take over a network of facilities, Japanese player Sawai says its aim is to “further increase production by strengthening the personnel structure.”
Cipla has provided the latest on its US complex pipeline ahead of several potential launches in the firm’s upcoming 2022/23 financial year. The Indian firm enjoyed 6% group revenue growth in Q3 FY2022 and is on track to hit its EBITDA margin target.